Author Affiliations
- B Friedrichs,
- M Tiemann,
- H Salwender,
- K Verpoort,
- MK Wenger and
- N Schmitz
Abstract
A 35-year old woman developed Burkitt's lymphoma and was treated with rituximab and CHOP therapy early during pregnancy. Monitoring of rituximab concentrations and B-cell counts in the child revealed a transient complete B-cell depletion associated with high rituximab cord blood concentrations. B-cell recovery was fast, showing a regular immunophenotype without loss of CD20 antigen, no functional deficits and adequate vaccination IgG titers.
Vol 91 Issue 10
Permalink:
Jump To
More in this TOC Section
Related Articles
Cited By...
- Anticancer drugs during pregnancy
- Cancer in pregnancy: disentangling treatment modalities
- High-risk pregnancy and the rheumatologist
- Biologic therapies and pregnancy: the story so far
- An Update on the Management of Hematologic Malignancies in Pregnancy
- Obstetrical, Fetal and Postnatal Effects of Gestational Antiblastic Chemotherapy: How to Counsel Cancer Patients
- Safety of rituximab therapy during twins' pregnancy
- Pregnancy outcomes after maternal exposure to rituximab
- Developmental Immunotoxicology Assessment of Rituximab in Cynomolgus Monkeys
- Developmental Toxicity Testing of Biopharmaceuticals in Nonhuman Primates: Previous Experience and Future Directions
- Oesophageal anomaly in a newborn after maternal exposure to mycofenolate mofetil
- Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab
- Management of lymphoma in pregnancy
- The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy